[HTML][HTML] Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation
LS Miguel, E Rocha, J Ferreira - Revista Portuguesa de Cardiologia …, 2013 - Elsevier
Abstract Introduction and Objectives To estimate the cost-effectiveness and cost-utility of
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …
dabigatran in the prevention of stroke and systemic embolism in patients with non-valvular …
Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain
JR González-Juanatey, J Álvarez-Sabin… - Revista Española de …, 2012 - Elsevier
INTRODUCTION AND OBJECTIVES: Assessment of the cost-effectiveness of dabigatran for
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …
the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …
What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.
J Jegathisawaran, A Holbrook, JM Bowen… - Journal of Population …, 2017 - europepmc.org
Objectives The introduction of new oral anticoagulants for the prevention of stroke in atrial
fibrillation (AF) has changed the clinical management of AF. To inform decision making …
fibrillation (AF) has changed the clinical management of AF. To inform decision making …
[HTML][HTML] Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective
J Chevalier, O Delaitre, F Hammès… - Archives of …, 2014 - Elsevier
Background Atrial fibrillation is the main cause of stroke, but the risk can be reduced, usually
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …
with vitamin K antagonists (VKAs) such as warfarin. The RE-LY atrial fibrillation study …
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack
Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …
Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
T Davidson, M Husberg, M Janzon… - European heart …, 2013 - academic.oup.com
Aims Patients with atrial fibrillation have a significantly increased risk of thromboembolic
events such as ischaemic stroke, and patients are therefore recommended to be treated with …
events such as ischaemic stroke, and patients are therefore recommended to be treated with …
[PDF][PDF] Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece
GK Andrikopoulos, V Fragoulakis… - Hellenic J …, 2013 - researchgate.net
Introduction: The objective of the present study was to evaluate, from an economic
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
AR Kansal, SV Sorensen, R Gani, P Robinson, F Pan… - Heart, 2012 - heart.bmj.com
Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …
[HTML][HTML] Cost-effectiveness and cost-utility analyses of dabigatran compared with warfarin in patients with nonvalvular atrial fibrillation and risk factors for stroke and …
CPR de Souza, NB Santoni, TG de Melo… - Value in health regional …, 2015 - Elsevier
Objective To analyze the cost-effectiveness and cost-utility of dabigatran compared with
warfarin in patients with nonvalvular atrial fibrillation with moderate to high risk of ischemic …
warfarin in patients with nonvalvular atrial fibrillation with moderate to high risk of ischemic …
Cost-effectiveness of dabigatran for stroke prevention in atrial fibrillation in Switzerland
M Pletscher, R Plessow, K Eichler… - Swiss medical …, 2013 - digitalcollection.zhaw.ch
Objectives: Atrial fibrillation is a major risk factor for ischemic stroke and anticoagulation
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …
therapy is indicated to reduce risk. Dabigatran is a new oral anticoagulant that does not …